Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 1/20 | 0.31 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25484070 | 0.85 | SLC2A1 (0.33) | SLC2A1EHMT2L3MBTL1ALDH1A1CYP1A2 | |
| SCHEMBL26323276 | 0.79 | ALDH1A1 (0.30) | L3MBTL1ALDH1A1MAPT | |
| SCHEMBL26323357 | 0.74 | ADRA2A (0.33) | POLBSMN1; SMN2 | |
| SCHEMBL26147165 | 0.71 | MAPT (0.32) | L3MBTL1POLBMAPTSMN1; SMN2 | |
| SCHEMBL26323238 | 0.69 | L3MBTL1 (0.33) | SLC2A1EHMT2L3MBTL1ALDH1A1MAPT | |
| SCHEMBL23999409 | 0.69 | LRRK2 (0.40) | SLC2A1EHMT2L3MBTL1POLBSMN1; SMN2 | |
| SCHEMBL23999480 | 0.69 | DNMT1 (0.38) | POLBMAPTSMN1; SMN2 | |
| SCHEMBL23999444 | 0.68 | KDR (0.39) | — | |
| SCHEMBL30180298 | 0.68 | KDR (0.39) | — | |
| SCHEMBL23999377 | 0.67 | MAPT (0.46) | SLC2A1POLBMAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230295114-A1 | AKT3 MODULATORS | Georgiamune Inc. | 2023-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295114-A1 | AKT3 MODULATORS | AKT3, AKT2, MTOR | SLC2A1 1038/4885EHMT2 4260/4885L3MBTL1 2295/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.